Appoints global biopharma leader Paul Carter

Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, is delighted to announce the appointment of Paul Carter as Non-Executive Director, effective 27 October 2025.

Paul Carter is a highly accomplished global biopharmaceutical leader with nearly three decades of senior executive experience spanning commercial, operational, and strategic leadership roles. He has built and scaled businesses across Europe, North America, and Asia, combining deep operational expertise with a proven record of driving transformational growth and delivering long-term shareholder value.

Paul currently serves as Non-Executive Chair of Clinigen Group plc, a leading global pharmaceutical services and supply company supporting access to medicines in over 120 countries. He is also Chair of Memo Therapeutics AG, a Swiss-based private clinical-stage biotech developing novel antibody therapeutics, and Chair of Kyowa Kirin International plc, the European subsidiary of Kyowa Kirin Co., Ltd. (TSE: 4151), a Japan-based global specialty pharmaceutical company. In addition, Paul serves as Non-Executive Director at Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company, pioneering TCR-based immunotherapies for cancer.

He previously held senior global roles including Executive Vice President and Chief Commercial Officer at Gilead Sciences, Inc. (NASDAQ: GILD), where he oversaw international operations across 38 markets and delivered annual revenues exceeding US$30 billion.

His appointment strengthens the Solvonis Board as the Company continues to advance its differentiated CNS pipeline and execute its capital-efficient, licensing-first growth strategy across addiction, psychiatry, and neurology.

Anthony Tennyson, Chief Executive Officer of Solvonis, commented: "We are delighted to welcome Paul to the Solvonis Board. He brings an exceptional depth of global leadership experience and strategic insight from some of the world's most successful pharmaceutical organisations. His expertise in scaling innovative science into global commercial success will be invaluable as Solvonis advances its CNS pipeline and builds towards the next phase of sustainable growth."

Paul Carter added: "Solvonis is building an exciting and differentiated CNS biopharmaceutical platform with significant potential to deliver impact for patients and value for shareholders. I look forward to working with Anthony and the Board to help shape strategy, strengthen partnerships, and support the Company's continued evolution and growth."

Option Grant

Mr Carter has been granted 21 million share options under the Company's existing long term incentive plan ("LTIP"), exercisable over ordinary shares of £0.001 each in Solvonis Therapeutics Plc at an exercise price of £0.0034 per share. The options have a three-year life and vest in three equal tranches: one-third on grant date, one-third on the first anniversary of grant date, and one-third on the second anniversary of grant.